Aging populations and clearer U.S. drug pricing boost long-term pharma outlook. Leaders like Eli Lilly and Merck lead in ...
This story is part of Forbes’ coverage of India’s Richest 2025. See the full list here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback